Lyon, Rhone-Alpes, France Sham appeared to be the Corporate Investor, which was created in 1927. The main department of described Corporate Investor is located in the Lyon. The company was established in Europe in France.
The top amount of exits for fund were in 2018. Comparing to the other companies, this Sham performs on 21 percentage points more the average number of lead investments. The fund is constantly included in less than 2 investment rounds annually. The high activity for fund was in 2013. Deals in the range of 5 - 10 millions dollars are the general things for fund.
The typical case for the fund is to invest in rounds with 3-4 participants. The meaningful sponsors for the fund in investment in the same round are Sofimac Partners, Omnes Capital, Octalfa. In the next rounds fund is usually obtained by Bpifrance, Qualcomm Ventures, Lundbeckfonden Ventures.
We can highlight the next thriving fund investment areas, such as Biotechnology, Information and Communications Technology (ICT). Among the most popular portfolio startups of the fund, we may highlight Glycode, EyeTechCare, Biom'Up. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - France. The fund has no specific favorite in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
Related Funds
| Fund Name | Location |
| Astra Ventura | Indonesia, Jakarta, Jakarta Raya |
| Cooperathon | Canada, Montreal, Quebec |
| Decibel Partners | California, Palo Alto, United States |
| Fenghai Capital | - |
| Hampstead Park Capital | - |
| Lundbeck | Denmark, Hovedstaden, Valby |
| Meyer Keith | - |
| Qlue | Indonesia, Jakarta, Jakarta Raya |
| Scotiabank | Canada, Ontario, Toronto |
| Wichita Technology Corporation (WTC) | Kansas, United States, Wichita |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
CyberMDX | $20M | 07 Apr 2020 | New York, United States | ||
Amolyt Pharma | $79M | 31 Jul 2019 | Écully, Rhone-Alpes, France | ||
EyeTechCare | $11M | 12 Mar 2013 | France, Auvergne-Rhône-Alpes | ||
Biom'Up | $8M | 26 Oct 2012 | France, New Aquitaine, France | ||
Glycode | $3M | 18 Jan 2010 | France, New Aquitaine, France |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
CyberMDX | $20M | 07 Apr 2020 | New York, United States | ||
Amolyt Pharma | $79M | 31 Jul 2019 | Écully, Rhone-Alpes, France | ||
EyeTechCare | $11M | 12 Mar 2013 | France, Auvergne-Rhône-Alpes | ||
Biom'Up | $8M | 26 Oct 2012 | France, New Aquitaine, France | ||
Glycode | $3M | 18 Jan 2010 | France, New Aquitaine, France |
